Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes

Diabetes

Volumn 57, Issue 12, 2008, Pages 3315-3322

  Briscoe, Vanessa J ^a   Ertl, Andrew C ^a   Tate, Donna B ^a   Davis, Stephen N ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b Department of Medicine Veterans Affairs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; FLUOXETINE; GLUCOSE; NORADRENALIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; INSULIN;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; BLOOD; HOMEOSTASIS; MIDDLE AGED; PHYSIOLOGY;

ADULT; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIA; INSULIN; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 58149357118     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-1000     Document Type: Article

References (41)

1. Sawka AM, Burgart V, Zimmerman D: Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. J Pediatr 136:394-396, 2000
2. Sawka AM, Burgart V, Zimmerman D: Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors. Diabetes Care 24:1845-1846, 2001
3. Perry KW, Fuller RW: Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 50:1683-1690, 1992
4. Perry KW, Fuller RW: Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J Neural Transm 104:953-966, 1997
5. 2 receptor antagonists on insulin-induced adrenomedullary catecholamine release. Neuroendocrinology 54: 639-645, 1991
6. 2 receptor agonist, DOI. Eur J Pharmacol 213:41-46, 1992
7. Blardi P, de Lalla A, Auteri A, Iapichino S, Dell'Erba A, Castrogiovanni P: Plasma catecholamine levels after fluox treatment in depressive patients. Neuropsychobiology 51:72-76, 2005
8. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW: Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 160:353-361, 2002
9. Briscoe VJ, Ertl AC, Tate DB, Dawling S, Davis SN: Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy man. Diabetes 57:2453-2460, 2008
10. Sanders NM, Wilkinson CW, Taborsky GJ, Salwa A, Daumen W, Zavosh A, Figlewicz DP: The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia. Am J Physiol Endocrinol Metab 294:E853-E860, 2008
11. Zung WW, Richards CB, Short MJ: Self-rating depression scale in an outpatient clinic: further validation of the SDS.A self-rating depression scale. Arch Gen Psychiatry 13:508-515, 1965
12. Carroll BJ, Fielding JM, Blashki TG: Depression rating scales: A critical review. Arch Gen Psychiatry 28:361-366, 1973
13. Abumrad NN, Rabin D, Diamond MC, Lacy WW: Use of a heated superficial hand vein as an alternative site for measurement of amino acid concentration and for the study of glucose and alanine kinetics in man. Metabolism 30:936-940, 1981
14. DeFronzo RA, Tobin K, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E216-E223, 1979
15. Amiel SA, Tambolane WV, Simonson DC, Sherwin R: Defective glucose counterregulation after strict control of insulin-dependent diabetes melli- tus. N Engl J Med 316:1376-1383, 1987
16. Davis SN, Shavers C, Costa F: Differential gender responses to hypoglyce- mia are due to alterations in CNS drive and not glycemic thresholds. Am J Physiol Endocrinol Metab 279:E1054-E1063, 2000
17. Wallin B, Sundiot G, Eriksson B, Domniak P, Grobecker H, Lindblad L: Plasma noradrenaline correlates by sympathetic muscle nerve activity in normotensive man. Acta Physiol Scand 11: 69-73, 1981
18. Sandoval D, Ertl AC, Richardson A, Tate D, Davis SN: Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes 52: 1749-1755, 2003
19. Wall JS, Steele R, Debodo RD, Altszuler N: Effect of insulin on utilization and production of circulating glucose. Am J Physiol 189:43-50, 1957
20. Aguilar-Parada E, Eisentraut AM, Unger RH: Pancreatic glucagon secretion in normal and diabetic subjects. Am, J Med Sci 257:415-419, 1969
21. Wide L, Porath J: Radioimmunoassay of proteins with the uses of sephadex-coupled antibodies. Biochim Biophys Acta 130:257-260, 1966
22. Causon R, Caruthers M, Rodnight R: Assay of plasma catecholamines by liquid chromatography with electrochemical detection. Anal Biochem 116:223-226, 1982
23. 131I]-labeled human growth hormone of high specific activity. Nature 194:495-496, 1962
24. Hagopian W, Lever EG, Cohen D, Emmanouel D, Polonsky KS, Pugh W, Moossa A, Jaspan JB: Predominance of renal and absence of hepatic metabolism of pancreatic polypeptide in the dog. Am J Physiol 245:171-177, 1983
25. Lloyd B, Burrin J, Smythe P, Alberti KG: Enzymatic fluorometric continuous flow assays for blood glucose, lactate, pyruvate, alanine, glycerol and 2-hydroxybutyrate. Clin Chem 24:1724-1729, 1978
26. Ho RJ: Radiochemical assay of long chain fatty acids using 63NI as tracer. Anal Biochem 26:105-113, 1970
27. Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ: Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron capture detection. J Chromatogr Biomed Appl 579:99 -106, 1992
28. Deary L, Hepburn D, Macleod K, Frier BM: Partitioning the symptoms of hypoglycemia using multi-sample confirmatory factor analysis. Diabetologia 36:771-770, 1993
29. Gerich J, Noacco C, Karam J, Forsham P: Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha-cell defect. Science 182:171, 1973
30. Cryer PE: Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 43:1378-1389, 1994
31. Davis SN, Shavers C, Davis B, Costa F: Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 100:429-438, 1997
32. Fanelli C, DeFeo P, Porcellati F, Perriello G, Torlone E, Santeusanio F, Brunetti P, Bolli GB: Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. J Clin Invest 89:2005-2013, 1992
33. Rizza R, Haymon M, Cryer P, Gerich J: Differential effects of epinephrine on glucose production and disposal in man. Am J Physiol Endocrinol Metab 237:E356-E362, 1979
34. Guy DA, Sandoval D, Richardson MA, Tate D, Flakoll PJ, Davis SN: Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans. Am J Physiol Endocrinol Metab 288:E178-E186, 2005
35. Teves D, Videen TO, Cryer PE, Powers WJ: Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia. Proc Natl Acad Sci USA 101:6217-6221, 2004
36. Mayberg H: Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830-843, 2003
37. Taborsky GJ, Ahren B, Mundinger TO, Mei Q, Havel PJ: Autonomic mechanism and defects in the glucagon response to insulin induced hypoglycemia. Diabetes Nutr Metab 15:318-322, 2000
38. Carvalho F, Barros D, Silva J, Rezende E, Soares M, Fregoneze J, De Castro e Silva E: Hyperglycemia induced by acute central fluoxetine administration: role of the central CRH system and 5-HT3 receptors. Neuropeptides 38:98-105, 2004
39. D-fenfluramine in the conscious rat. J Pharmacol Exp Ther 260:1008-1016, 1992
40. Durand M, Berton O, Aguerre S, Edno L, Combourieu I, Mormede P, Chaouloff F: Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis in SHR and WKY rats. Neuropharmacology 38:893-907, 1999
41. Schleis T: Realities of the fluoxetine-to-sertraline switch. Am, J Health Syst Pharm 52:423, 1995